Comirnaty

BIOLOGICAL18 trials

Sponsors

Universitätsklinikum Hamburg-Eppendorf, Medical University Innsbruck, Jules Bordet Institute, Sinocelltech Ltd., Bavarian Nordic

Conditions

COVID-19COVID-19 DiseaseCancerChildhood cancer, Corona vaccination, immune response Childhood cancer, Corona vaccination, immune responseCovid19InfluenzaInfluenza, HumanSARS-CoV-2 Infection

Phase 1

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

CompletedNCT04569383

Universitätsklinikum Hamburg-EppendorfCovid19

Start: 2020-10-05End: 2021-08-24Updated: 2021-11-05

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Walvax Biotechnology Co., Ltd.COVID-19

Start: 2022-12-31End: 2023-06-30Target: 120Updated: 2022-11-18

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Walvax Biotechnology Co., Ltd.COVID-19

Start: 2022-07-31End: 2023-07-31Target: 120Updated: 2022-05-31

Phase 2

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2

Medical University InnsbruckSARS-CoV2 Infection

Start: 2021-05-10End: 2021-12-30Target: 3000Updated: 2021-09-10

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Sinocelltech Ltd.COVID-19, Sars-CoV-2 Infection

Start: 2022-03-20End: 2023-05-01Target: 360Updated: 2022-03-02

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-03-20End: 2022-12-01Target: 600Updated: 2022-03-02

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-04-01End: 2023-08-01Target: 400Updated: 2022-04-11

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

WithdrawnNCT05239975

Sinocelltech Ltd.COVID-19, SARS-CoV2 Infection

Start: 2022-04-25End: 2023-02-01Updated: 2024-02-09

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-07-01End: 2023-03-01Target: 400Updated: 2022-04-14

Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose

Instituto de Investigación Hospital Universitario La PazCovid19

Start: 2021-04-22End: 2022-12-30Target: 600Updated: 2022-05-18

Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly

TerminatedNCT05977127

Radboud University Medical CenterCOVID-19, Vaccination; Infection

Start: 2023-09-26End: 2024-03-21Updated: 2024-03-28

Phase 3

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Sinocelltech Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-05-30End: 2023-05-01Target: 1800Updated: 2023-04-10

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

CompletedNCT05329220

Bavarian NordicCOVID-19 Disease

Start: 2022-08-30End: 2023-10-05Updated: 2025-02-24

A comparison of the safety and immune response profiles between the new Pfizer-BioNTech Omicron adapted COVID-19 vaccine and the original Pfizer-BioNTech COVID-19 vaccine in previously unvaccinated adults in East Africa.

Active, not recruitingPACTR202306533302513

Start: 2023-04-17Target: 580Updated: 2026-08-03

Phase 4

Immune response following COVID-19 vaccination in children with cancer

Active, not recruitingNL-OMON21465

Princess Máxima Center for Pediatric OncologyChildhood cancer, Corona vaccination, immune response Childhood cancer, Corona vaccination, immune response

Start: 2021-07-17Target: 130Updated: 2024-06-11

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

TerminatedNCT05075538

Jules Bordet InstituteCancer

Start: 2021-12-01End: 2024-01-08Updated: 2024-01-17

Unknown Phase

Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine

CompletedNCT05781191

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCOVID-19, Influenza

Start: 2021-11-13End: 2021-12-31Updated: 2024-03-18

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

CompletedNCT05858450

PfizerCOVID-19, Influenza, Human

Start: 2023-05-05End: 2023-05-12Updated: 2024-09-20

Related Papers

Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.

2025-09-15

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Vaccines2025-01-07

MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity

Frontiers in Immunology2024-12-192 citations

Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial

Nature Communications2024-07-245 citations

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST

Open Forum Infectious Diseases2023-11-27

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

2023-09-0820 citations

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

2023-07-0815 citations

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.

2023-01-1829 citations

A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants

Science China Life Sciences2022-12-3029 citations

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.

2022-12-0525 citations

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Nature Communications2022-07-1920 citations

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.

2022-05-2331 citations

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.

2022-03-0941 citations